Effect of beta glucan coating on controlled release, bioaccessibility, and absorption of β-carotene from loaded liposomes.

Recently, the use of biopolymers as coating material to stabilise phospholipid-based nanocarriers has increased. One such class of biopolymers is the dietary fibre beta-glucan (βG). In this study, we developed and characterized beta-carotene (βC) loaded βG coated nanoliposomes (GNLs) to investigate the effect of βG coating on the stability, controlled release, bioaccessibility, diffusion and subsequent absorption of the lipophilic active agent.

Active Composite Packaging Reinforced with Nisin-Loaded Nano-Vesicles for Extended Shelf Life of Chicken Breast Filets and Cheese Slices.

Unlabelled: To meet the demands for more effective and ecofriendly food packaging strategies, the potential of nisin-loaded rhamnolipid functionalized nanofillers (rhamnosomes) has been explored after embedding in hydroxypropyl-methylcellulose (HPMC) and κ-carrageenan (κ-CR)-based packaging films. It was observed that intrinsically active rhamnosomes based nanofillers greatly improved the mechanical and optical properties of nano-active packaging (NAP) films. Incorporation of rhamnosomes resulted in higher tensile strength (5.

Improving carvacrol bioaccessibility using core-shell carrier-systems under simulated gastrointestinal digestion.

The impact of encapsulating carvacrol in chitosan-albumin based core-shell nano-carriers (NCs) on its stability and bioaccessibility was determined under simulated digestion conditions. These NCs consisted of chitosan (C) core enclosed by bovine serum albumin (BSA) shell. The mean particle size ranged from 52.

Impact of albumin corona on mucoadhesion and antimicrobial activity of carvacrol loaded chitosan nano-delivery systems under simulated gastro-intestinal conditions.

Emerging antibiotic resistance in pathogens has posed considerable challenges to explore and examine the natural antimicrobials (NAMs). Due to the labile nature of NAMs, nano-delivery systems (NDS) are required to protect them from physiological degradation and allow controlled delivery to the targeted site of infection. In this study, corona modified NDS were developed using bovine serum albumin (BSA) on a chitosan core (CS) for sustained delivery of carvacrol (CAR), a natural antimicrobial agent, in the intestine.

Alginate-caseinate based pH-responsive nano-coacervates to combat resistant bacterial biofilms in oral cavity.

Biofilm associated microbial resistance is a major concern in oral health and hygiene. Nano-antimicrobials (NAMs) having natural antibiotic replacers e.g.

Chitosan-albumin based core shell-corona nano-antimicrobials to eradicate resistant gastric pathogen.

In this study, protein/polysaccharide core-shell-corona (PP-CSC) nano delivery systems (NDS) were prepared by using bovine serum albumin (BSA) and chitosan (CS). The potential of PP-CSC-NDS for increasing the stability and bio-accessibility of ε-poly-l-lysine (ε-PL) as effective therapy for gastric Helicobacter pylori was investigated. The presence of CS-shell increased the size (223 ± 1.

Polyelectrolyte Multicomponent Colloidosomes Loaded with Nisin Z for Enhanced Antimicrobial Activity against Foodborne Resistant Pathogens.

Food grade micro- or nano-carrier systems (NCS) are being developed to improve the controlled release of antimicrobial agents. To augment the stability of liposomal NCS and to overcome the limitations associated with the use of free bacteriocin (nisin) in the food system, multi-component colloidosomes (MCCS) were developed by electrostatic interactions between anionic alginate and cationic chitosan (multilayer) around phospholipids based liposomes (core). Zeta-sizer results revealed the average diameter of 145 ± 2 nm, 596 ± 3 nm, and 643 ± 5 nm for nano-liposome (NL), chitosomes (chitosan coated NL) and MCCS, respectively.

Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics.

Background: Global death rate due to cardiovascular diseases (CVDs) is highest as compared to other ailments. Principal risk factor associated with CVDs is hypertension. Major classes of current antihypertensive (AHT) therapies include angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs).